Edgewise Therapeutics, Inc. EWTX
41.57 USD -0.47 (-1.12%)
As ofNov 18, 2026, 3:33 PM EST
40.33 Day range 42.37
19.76 52-week range 48.78
- YTD
- +67.49%
- 1 year
- +87.59%
News
benzinga.com Wedbush Maintains Outperform on Edgewise Therapeutics, Lowers Price Target to $51 Wedbush analyst Laura Chico maintains Edgewise Therapeutics (NASDAQ:EWTX) with a Outperform and lowers the price target from $53 to $51.
benzinga.com Edgewise Therapeutics Says Edgewise Has Submitted STRATUS-HCM Phase 3 Protocol Following End-Of-Phase 2 Meeting – STRATUS-HCM includes two independent placebo-controlled studies of symptomatic obstructive and nonobstructive HCM populations under a single master protocol, with peak VO₂ as the primary endpoint…
benzinga.com Edgewise Therapeutics Q3 Adj. EPS $(0.19) Misses $2.48 Estimate Edgewise Therapeutics (NASDAQ:EWTX) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $2.48 by 107.66 percent. This is a 51.28 percent increase over losses…
